Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
| ▸ | GRK5 | P34947 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851752 | 0.85 | CYP2E1 (0.36) | PTGS1PTGS2 | |
| SCHEMBL4856735 | 0.85 | CHEK1 (0.33) | PTGS1PTGS2CHEK2 | |
| SCHEMBL4812977 | 0.84 | PTGS1 (0.34) | PTGS1PTGS2CHEK2 | |
| SCHEMBL4845511 | 0.83 | TLR7 (0.38) | PTGS1PTGS2CHEK2DHFR | |
| SCHEMBL4876491 | 0.82 | KDM4E (0.36) | PTGS1PTGS2CHEK2 | |
| SCHEMBL4869849 | 0.81 | PTGS1 (0.38) | PTGS1PTGS2METAP2METAP1GRK5 | |
| SCHEMBL4867771 | 0.80 | PTGS1 (0.31) | PTGS1PTGS2 | |
| SCHEMBL14194760 | 0.77 | PDE10A (0.39) | PTGS1PTGS2METAP2METAP1GRK5 | |
| SCHEMBL4902397 | 0.76 | AKT1 (0.30) | CHEK2 | |
| SCHEMBL4810368 | 0.72 | PDE4B (0.36) | METAP2METAP1GRK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| WO-2008004117-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PDE5A, PDE3B, PDE12 | PTGS1 527/4885PTGS2 854/4885CHEK2 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.